News Focus
News Focus
Followers 60
Posts 11411
Boards Moderated 0
Alias Born 01/31/2008

Re: RedShoulder post# 335590

Thursday, 11/11/2021 8:16:07 AM

Thursday, November 11, 2021 8:16:07 AM

Post# of 518933
Thanks Red, for working to get this encouraging info!

1. Top Line AVATAR
2. Top Line Phase 1 Anavex 3-71
3. Initiation of Phase 2/3 Fragile X
4. Initiation of Phase 2/3 Clinical Trial for new rare disease

Also, Missling has implied earlier in the year that Anavex would be engaging in dialogue with the FDA regarding fast track approval and break through designation of 2-73 to treat Rett Syndrome.

From IR today:

I am pleased to say that as of today we do expect the catalysts you mentioned in your email to be attained accordingly. expectations may change.... if and when this were to occur we would make public such information in accordance with Regulation FD.

With respect to dialogue with FDA regarding Rett Syndrome - We can not comment on current or potential dialogue in a private manner, such as this email. ... we do understand the eagerness on behalf of investors and medical community for us to disclose at the earliest possible time information and progress with the FDA.


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News